Stifel Financial Corp Alaunos Therapeutics, Inc. Transaction History

Stifel Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.09 - $3.09 $48,090 - $71,100	-23,010 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.39 - $3.43 $131,019 - $188,032	-54,820 Reduced 70.44%	23,010 $57,000
Q2 2020 Aug 14, 2020	BUY	$2.2 - $3.71 $57 - $96	26 Added 0.03%	77,830 $255,000
Q3 2019 Nov 13, 2019	SELL	$4.13 - $6.94 $144 - $242	-35 Reduced 0.04%	77,804 $333,000
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $258 - $403	-65 Reduced 0.08%	77,839 $453,000
Q1 2019 May 14, 2019	SELL	$2.0 - $4.4 $112 - $246	-56 Reduced 0.07%	77,904 $300,000
Q4 2018 Feb 13, 2019	SELL	$1.61 - $3.62 $2,777 - $6,244	-1,725 Reduced 2.16%	77,960 $145,000
Q3 2018 Nov 13, 2018	BUY	$2.26 - $3.27 $49,719 - $71,940	22,000 Added 38.14%	79,685 $255,000
Q2 2018 Aug 14, 2018	SELL	$3.02 - $4.94 $78 - $128	-26 Reduced 0.05%	57,685 $173,000
Q1 2018 May 11, 2018	BUY	$3.46 - $5.14 $5,947 - $8,835	1,719 Added 3.07%	57,711 $226,000
Q4 2017 Feb 14, 2018	SELL	$4.0 - $6.54 $516 - $843	-129 Reduced 0.23%	55,992 $231,000
Q3 2017 Nov 13, 2017	BUY	$4.99 - $6.57 $280,043 - $368,714	56,121	56,121 $0

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.